Rituximab demonstrates significant real-world effectiveness and acceptable safety in Sjögren’s disease: Evidence from the PORTRESS registry
Anifrolumab demonstrates rapid and sustained disease control in real-world systemic lupus erythematosus study
RA flares assessed by FLARE-RA questionnaire linked to disease activity measures but not structural damage progression
Tight-control strategy with golimumab achieves high remission rates in early axial spondyloarthritis regardless of gut inflammation
Radiographic non-progression linked to greater low disease activity achievement in psoriatic arthritis patients on secukinumab
Dual-targeting chimeric antigen receptor T-cell therapy achieves prolonged remission in refractory systemic lupus erythematosus
Age and anti-ccp antibody levels identified as key risk factors for peripheral neuropathy in rheumatoid arthritis patients
